Annovis Bio Inc (ANVS)
7.65
-0.58
(-7.05%)
USD |
NYSE |
May 22, 16:00
7.63
-0.02
(-0.26%)
After-Hours: 20:00
Annovis Bio Cash from Operations (TTM): -35.37M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -35.37M |
December 31, 2023 | -39.97M |
September 30, 2023 | -34.21M |
June 30, 2023 | -28.83M |
March 31, 2023 | -25.92M |
December 31, 2022 | -17.31M |
September 30, 2022 | -15.47M |
June 30, 2022 | -13.23M |
March 31, 2022 | -9.679M |
December 31, 2021 | -9.132M |
September 30, 2021 | -8.129M |
Date | Value |
---|---|
June 30, 2021 | -7.308M |
March 31, 2021 | -5.475M |
December 31, 2020 | -3.971M |
September 30, 2020 | -3.257M |
June 30, 2020 | -2.379M |
March 31, 2020 | -1.218M |
December 31, 2019 | -0.4765M |
September 30, 2019 | -0.5002M |
June 30, 2019 | -0.5843M |
March 31, 2019 | -0.6304M |
December 31, 2018 | -0.5586M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-39.97M
Minimum
Dec 2023
-0.4765M
Maximum
Dec 2019
-13.12M
Average
-8.630M
Median
Cash from Operations (TTM) Benchmarks
ANI Pharmaceuticals Inc | 115.80M |
Ligand Pharmaceuticals Inc | 34.36M |
FibroGen Inc | -272.72M |
SINTX Technologies Inc | -11.98M |
Stereotaxis Inc | -8.683M |